J Lin

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi request reprint Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
    Senthamil R Selvan
    Division of Solid Tumor, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA
    Curr Cancer Drug Targets 16:755-764. 2016
  2. doi request reprint Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions
    Jianqing Lin
    Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Semin Oncol 40:393-401. 2013
  3. doi request reprint Targeting angiogenesis as a promising modality for the treatment of prostate cancer
    Jianqing Lin
    Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Urol Clin North Am 39:547-60. 2012
  4. ncbi request reprint HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides
    J Lin
    Jefferson Kimmel Cancer Center, 834 Chestnut Street, Suite 314, Philadelphia, PA 19107, USA
    Curr Cancer Drug Targets 9:881-7. 2009
  5. doi request reprint Hospital-based costs associated with venous thromboembolism treatment regimens
    G Merli
    Jefferson Center for Vascular Diseases, Thomas Jefferson University, Philadelphia, PA, USA
    J Thromb Haemost 6:1077-86. 2008
  6. doi request reprint Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: an analysis of an integrated healthcare database
    G J Merli
    Jefferson Vascular Center, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, USA
    J Thromb Thrombolysis 32:89-95. 2011

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
    Senthamil R Selvan
    Division of Solid Tumor, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA
    Curr Cancer Drug Targets 16:755-764. 2016
    ..IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation...
  2. doi request reprint Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions
    Jianqing Lin
    Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Semin Oncol 40:393-401. 2013
    ..Combinations of epigenetic agents alone or with a targeted agent such as androgen receptor signaling inhibitors are promising approaches and will be discussed further. ..
  3. doi request reprint Targeting angiogenesis as a promising modality for the treatment of prostate cancer
    Jianqing Lin
    Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Urol Clin North Am 39:547-60. 2012
    ..Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach...
  4. ncbi request reprint HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides
    J Lin
    Jefferson Kimmel Cancer Center, 834 Chestnut Street, Suite 314, Philadelphia, PA 19107, USA
    Curr Cancer Drug Targets 9:881-7. 2009
    ..The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed...
  5. doi request reprint Hospital-based costs associated with venous thromboembolism treatment regimens
    G Merli
    Jefferson Center for Vascular Diseases, Thomas Jefferson University, Philadelphia, PA, USA
    J Thromb Haemost 6:1077-86. 2008
    ..With upcoming US national performance measures requiring successful implementation of evidence-based therapy, cost considerations for anticoagulant choice are of increasing importance to hospitals...
  6. doi request reprint Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: an analysis of an integrated healthcare database
    G J Merli
    Jefferson Vascular Center, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, USA
    J Thromb Thrombolysis 32:89-95. 2011
    ..Further efforts are required to ensure the recommended duration of thromboprophylaxis is prescribed to all patients and continued outpatient VTE prophylaxis is provided...